Your browser doesn't support javascript.
loading
Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC) 2016.
Lugli, Alessandro; Kirsch, Richard; Ajioka, Yoichi; Bosman, Fred; Cathomas, Gieri; Dawson, Heather; El Zimaity, Hala; Fléjou, Jean-François; Hansen, Tine Plato; Hartmann, Arndt; Kakar, Sanjay; Langner, Cord; Nagtegaal, Iris; Puppa, Giacomo; Riddell, Robert; Ristimäki, Ari; Sheahan, Kieran; Smyrk, Thomas; Sugihara, Kenichi; Terris, Benoît; Ueno, Hideki; Vieth, Michael; Zlobec, Inti; Quirke, Phil.
Affiliation
  • Lugli A; Institute of Pathology, University of Bern, Bern, Switzerland.
  • Kirsch R; Pathology and Laboratory Medicine, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada.
  • Ajioka Y; Division of Molecular and Diagnostic Pathology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
  • Bosman F; University Institute of Pathology, Lausanne University Medical Center, Lausanne, Switzerland.
  • Cathomas G; Institute of Pathology, Kantonsspital Liestal, Liestal, Switzerland.
  • Dawson H; Institute of Pathology, University of Bern, Bern, Switzerland.
  • El Zimaity H; Dynacare Laboratory, Brampton, Ontario, Canada.
  • Fléjou JF; Pathology Department, Saint-Antoine Hospital, Pierre et Marie Curie University, Paris, France.
  • Hansen TP; Department of Pathology, Copenhagen University Hospital, Herlev, Denmark.
  • Hartmann A; Department of Pathology, University Hospital Erlangen, Erlangen, Germany.
  • Kakar S; Department of Anatomic Pathology, University of California, San Francisco, CA, USA.
  • Langner C; Institute of Pathology, Medical University of Graz, Graz, Austria.
  • Nagtegaal I; Department of Pathology, Radboud University Medical Centre, Nijmegen, The Netherlands.
  • Puppa G; Department of Clinical Pathology, Geneva University Hospital, Geneva, Switzerland.
  • Riddell R; Pathology and Laboratory Medicine, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada.
  • Ristimäki A; Department of Pathology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
  • Sheahan K; Department of Pathology, St Vincent's University Hospital, Dublin, Ireland.
  • Smyrk T; Divisions of Anatomic Pathology and Mayo Clinic, Rochester, MN, USA.
  • Sugihara K; Department of Surgical Oncology, Tokyo Medical and Dental University, Graduate School of Medical and Dental Sciences, Bunkyo-ku, Tokyo, Japan.
  • Terris B; Pathology Department, Hôpital Cochin and Université Paris Descartes Sorbonne Paris Cité, Paris, France.
  • Ueno H; Department of Surgery, National Defense Medical College, Tokorozawa, Saitama, Japan.
  • Vieth M; Institute of Pathology, Klinikum Bayreuth, Bayreuth, Germany.
  • Zlobec I; Institute of Pathology, University of Bern, Bern, Switzerland.
  • Quirke P; Pathology and Tumour Biology, University of Leeds, St James's University Hospital, Leeds, UK.
Mod Pathol ; 30(9): 1299-1311, 2017 09.
Article in En | MEDLINE | ID: mdl-28548122
Tumor budding is a well-established independent prognostic factor in colorectal cancer but a standardized method for its assessment has been lacking. The primary aim of the International Tumor Budding Consensus Conference (ITBCC) was to reach agreement on an international, evidence-based standardized scoring system for tumor budding in colorectal cancer. The ITBCC included nine sessions with presentations, a pre-meeting survey and an e-book covering the key publications on tumor budding in colorectal cancer. The 'Grading of Recommendation Assessment, Development and Evaluation' method was used to determine the strength of recommendations and quality of evidence. The following 10 statements achieved consensus: tumor budding is defined as a single tumor cell or a cell cluster consisting of four tumor cells or less (22/22, 100%). Tumor budding is an independent predictor of lymph node metastases in pT1 colorectal cancer (23/23, 100%). Tumor budding is an independent predictor of survival in stage II colorectal cancer (23/23, 100%). Tumor budding should be taken into account along with other clinicopathological features in a multidisciplinary setting (23/23, 100%). Tumor budding is counted on H&E (19/22, 86%). Intratumoral budding exists in colorectal cancer and has been shown to be related to lymph node metastasis (22/22, 100%). Tumor budding is assessed in one hotspot (in a field measuring 0.785 mm2) at the invasive front (22/22, 100%). A three-tier system should be used along with the budding count in order to facilitate risk stratification in colorectal cancer (23/23, 100%). Tumor budding and tumor grade are not the same (23/23, 100%). Tumor budding should be included in guidelines/protocols for colorectal cancer reporting (23/23, 100%). Members of the ITBCC were able to reach strong consensus on a single international, evidence-based method for tumor budding assessment and reporting. It is proposed that this method be incorporated into colorectal cancer guidelines/protocols and staging systems.
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pathology, Clinical / Colorectal Neoplasms / Cell Movement Type of study: Guideline / Prognostic_studies / Qualitative_research Limits: Humans Language: En Journal: Mod Pathol Journal subject: PATOLOGIA Year: 2017 Document type: Article Affiliation country: Switzerland Country of publication: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pathology, Clinical / Colorectal Neoplasms / Cell Movement Type of study: Guideline / Prognostic_studies / Qualitative_research Limits: Humans Language: En Journal: Mod Pathol Journal subject: PATOLOGIA Year: 2017 Document type: Article Affiliation country: Switzerland Country of publication: United States